| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Phio Pharmaceuticals Corp. (PHIO) has 7 insiders with recent SEC Form 4 filings, including 18 buys and 0 sells. PHIO is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 411.4K | $534.8K | - | |
| CFO | 94.0K | $122.2K | - | |
| Dir | 45.7K | $59.3K | - | |
| Dir | 38.7K | $50.3K | - | |
| Dir | 37.8K | $49.1K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Jun 23, 2017 | Dispersyn Gerrit | Chief Development Officer | Buy | 3,500 | $0.62 | $2,170.00 | New | |
| Jun 22, 2017 | Cauwenbergh Geert | President &CEO | Buy | 10,000 | $0.63 | $6,250.00 | +4.3% | |
| Apr 26, 2017 | Cauwenbergh Geert | President &CEO | Buy | 10,000 | $0.65 | $6,480.00 | +9.7% | |
| Mar 17, 2017 | Cauwenbergh Geert | President &CEO | Buy | 10,000 | $0.77 | $7,692.01 | +3.4% | |
| Feb 17, 2017 | Cauwenbergh Geert | President &CEO | Buy | 10,000 | $0.69 | $6,931.40 | +3.9% | |
| Feb 8, 2017 | Cauwenbergh Geert | President &CEO | Buy | 10,000 | $0.69 | $6,850.00 | +13.8% | |
| Jan 25, 2017 | Cauwenbergh Geert | President &CEO | Buy | 10,000 | $0.70 | $6,965.96 | +8.0% | |
| Jan 19, 2017 | Cauwenbergh Geert | President &CEO | Buy | 10,000 | $0.69 | $6,948.74 | +5.8% | |
| Apr 2, 2015 | Cauwenbergh Geert | President &CEO | Buy | 5,000 | $0.72 | $3,596.00 | +8.0% | |
| Feb 17, 2015 | Cauwenbergh Geert | President &CEO | Buy | 4,000 | $1.17 | $4,680.00 | +6.8% |